Regulation of the Epithelial Sodium Channel (ENaC) by the Short Palate, Lung, and Nasal Epithelial Clone (SPLUNC1) by Rollins, Brett
 
 
 
 
 
 
 
 
 
 
Regulation of the Epithelial Sodium Channel (ENaC) by the Short Palate, Lung, and 
Nasal Epithelial Clone (SPLUNC1) 
 
 
 
 
 
Brett Rollins 
 
 
 
 
A thesis submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Master of Science in the 
Department of Cell and Molecular Physiology 
 
 
 
 
Chapel Hill 
2010 
 
 
 
 
Approved by 
 
Dr. James Anderson 
Dr. P. Kay Lund 
Dr. Robert Tarran 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2010 
Brett Matthew Rollins 
ALL RIGHTS RESERVED 
 
 iii 
 
 
 
 
 
Abstract 
Brett Rollins: Regulation of the Epithelial Sodium Channel (ENaC) by the Short Palate, 
Lung, and Nasal Epithelial Clone (SPLUNC1) 
(Under the direction of Robert Tarran) 
 
The airways rely on mucociliary clearance (MCC) to remove inhaled particulates. 
Initiating events in chronic airway diseases, such as cystic fibrosis (CF), have been traced 
back to the failure of a critical MCC component, ion transport. Specifically, the epithelial 
sodium channel (ENaC) is known to be hyperabsorptive in CF airway epithelia and 
contributes to dehydrated airway surface liquid (ASL), collapsed cilia, and high percent 
solid mucus.  Recently, proteolytic cleavage and activation of ENaC has been described 
and SPLUNC1 was identified as an endogenous inhibitor of ENaC activation.  Here, we 
demonstrate SPLUNC1’s ability to reduce macroscopic current and specifically the 
number of channels of membrane-inserted ENaCs.  This work also identifies the active 
site of SPLUNC1 and provides evidence for a functional SPLUNC1 mimetic peptide.  
Further, as nonfunctional CFTR influences abnormal bicarbonate secretion and thus CF 
ASL pH, we correlated the loss of SPLUNC1’s function in CF airways to this acidic 
environment.   
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Chapter 1 
REGULATION OF MUCOCILIARY CLEARANCE 
 
Introduction 
 As the airway is constantly exposed to inhaled challenges, it is appropriately 
equipped to prevent injury and disease.  The first line of defense against the inhaled 
particulates is a layer of mucus that rests above a periciliary liquid layer (Matsui, Grubb 
et al. 1998; Matsui, Randell et al. 1998; Knowles and Boucher 2002).  The height of this 
layer is maintained by ion transport so that ciliary beating is efficiently translated to 
movement, and subsequent clearance, of the mucus containing trapped particulates.  
Together mucus secretion, ion transport, and cilia beating comprise the mucociliary 
clearance (MCC) mechanism.  In addition to the direct results from the proper regulation 
of each MCC component, the coordination of MCC component interactions is vital for 
maintaining host defense.  Genetic abnormalities, infectious agents, or toxins, however, 
disrupt this regulation and allow pathogenesis to ensue, thereby illustrating the role of 
MCC regulation as a vital defense system in the airway.  Examples of such MCC 
component impairment and subsequent disease states include Cystic Fibrosis (CF), 
Chronic Obstructive Pulmonary Disorder (COPD), and Primary Ciliary Dyskinesis 
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(PCD).  This chapter will explain current understandings of the MCC components in the 
normal condition as well as in these diseased states.   
 
 
 
 
I.  Healthy State Mucociliary Clearance 
 Under healthy conditions, the three mucus components are individually regulated 
and properly coordinated with one another.  This includes entrapment of inhaled 
particulates in an adequately hydrated mucus layer that rests above the periciliary liquid 
layer, which combined comprise the airway surface liquid (ASL).  Ion transport 
regulation defines the correct height of this layer so that cilia originating from underlying 
epithelial cells may be outstretched.  Functioning in an ASL of correct composition 
allows the cilia to beat against the mucus layer to propel the inhaled particulates away 
from the airway.  
 
1.  Mucus Regulation 
1.1 Mucus 
 The mucus layer is the MCC component that provides the first line of defense 
against inhaled particulates.  This layer is an aqueous solution composed of lipids, 
glycoconjugates, proteins, electrolytes, enzymes, anti-enzymes, oxidants, anti-oxidants, 
exogenous bacteria, endogenous anti-bacterial secretions, cell and plasma derived 
mediators and proteins, and cellular debris (Rogers 2007).  Within this solution, mucins 
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are responsible for the non-newtonian, viscoelastic properties that allow for efficient 
translation of ciliary beating force as well as the bacterial recognition abilities of this 
layer (Chen and Dulfano 1978). 
 
 
 
1.2 Mucins 
 Under normal conditions, mucins compose approximately 2% by weight of the 
mucus layer (Davies, Herrmann et al. 2002).  In the airways mucins are produced by 
goblet cells while in submucosa they are produced by sero-mucous glands (Rogers 2002).   
The expressed mucin genes are translated to form a linear peptide backbone termed, 
apomucin.  Mucin post-translational modifications include O-linked carbohydrate side 
chains and N-linked glycans (Hanisch 2001).  Tandemly repeated serine and threonine 
sequences provide the mucin with sites for glycosylation (Rose and Voynow 2006).  
These decorations provide diversification and specification for bacterial recognition 
along with mucin localization (Dell and Morris 2001; Hanisch 2001; Moniaux, Escande 
et al. 2001).  Collectively, mucins can be classified as either secreted or membrane 
associated.  Within the airway membrane tethered mucins include MUC 1, 3a, 3b, 4, 12, 
13, 15, 16, 17, and 20 while the secreted mucins include MUC 2, 5AC, 5B, 6, and 19.  
Protein cross links and entanglements among these mucins lead to the gel like properties 
of mucus (Raynal, Hardingham et al. 2003).  Of the secreted genes, MUC2, 5AC, 5b, and 
6 have been identified as a four gene cluster on chromosome 11.  Mucin promoters for 
various MUC genes are distinct from one another, although epigenetic alteration of 
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chromosome 11 can have broad consequences on MUC expression (Vincent, Perrais et al. 
2007; Thai, Loukoianov et al. 2008). 
 Within the airways, the major secreted and gel-forming mucins are MUC5AC and 
MUC5B. The PCL is a grafted polyanionic gel composed of mucins 1, 4, 13, and 16, 
which are different than those found in the mucus layer.  Here, these mucins are tethered 
to the cell surface.  The concentrations of mucins differ between these two layers.   
These repulsive forces generated between the polyanionic mucins are proportional to 
their concentration and generates an osmotic pressure.  As a result, the osmotic pressures 
between the two ASL components differ.  Under normal condition, the PCL has a greater 
osmotic pressure than the mucus layer.  New insight into this field will advance 
understanding of mucus hydration.   
 
1.3 Mucin gene expression 
Baseline levels of mucin expression and secretion are beneficial for airways.  
Overproduction and hypersecretion of mucins, however, must be paired with adequate 
levels of hydration and clearance to maintain its protective role.  Furthermore, a loss of 
coordination between mucus secretion, ion transport, and cilia function contributes to 
pathogenesis as infectious or noxious agents fail to be cleared from the now static mucus 
layer.   
Mucin gene expression may be influenced by several factors including inhaled 
chemical and infectious agents.  Endogenous mediators include inflammatory cytokines 
and growth factors.  Many of the signaling cascades that control this expression are now 
understood (Thai, Loukoianov et al. 2008).  This regulated expression allows mucin 
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production to be a responsive defense mechanism to threats presented to the host.  For 
instance, bacterial products such as LPS or LTA can trigger MAP-kinase pathways to 
activate NF-kB, which subsequently is capable of promoting mucin expression such as 
MUC5AC (Li, Gallup et al. 1998).  Inflammation responses can further influence mucin 
gene expression.  Activated neutrophils, for instance, trigger TGF-α pathways to increase 
expression (Song, Cho et al. 2005).  Conversely, anti-inflammatory pharmacological 
agents are able to inhibit mucin transcription (Shimizu, Shimizu et al. 2003).  Mucin 
expression is responsive to other environmental challenges such as oxidative agents.  
Nitric oxide has been shown to induce airway epithelial MUC5AC via a PKC and ERK 
dependent pathway (Song, Kang et al. 2007).  Dual oxidase 1 (Duox 1) is also found in 
airway epithelium, and via ROS generation, activates TACE.  This enzyme then converts 
TGF-α to its soluble form that triggers mucin expression (Shao and Nadel 2005).  As an 
example, cigarette smoke is a common source of such oxidative agents and likely triggers 
these pathways and affects such pathways (Chow 1993). 
 
1.4 Mucus Secretion 
The hydration and subsequent decompression of mucins, follows controlled 
exocytosis and secretion.  As has previously been reviewed, this regulation involves actin 
filament disruption and remodeling, as well as mucin secretory granule positioning, 
docking, priming, and exocytosis (Davis and Dickey 2008). 
 Exocytosis of mucin granuels follows first order kinetics and occurs in tens of 
milliseconds.  Prior to release, the polyanionic mucins are charge-shielded from one 
another by Ca2+ ions within the vesicle (Verdugo, Deyrup-Olsen et al. 1987). In order to 
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release the vesicular content into the airway the soluble N- ethyl sensitive factor 
attachment protein receptor (SNARE) complex system is utilized.  Mucin containing 
vesicles are labeled with v-SNARE and become associated with the t-SNARE labeled 
membrane.  Another important component of exocytosis is actin/myosin contraction.  
This contraction is regulated by MARCKS phosphorylation by protein kinase C, allowing 
cytoplasmic relocation and interaction with mucin vesicles.  This leads to actin/myosin 
contraction so that the vesicle fuses with the plasmalemma (Park, Fang et al. 2008).  
Furthermore, another set of exocytosis regulatory proteins know as Munc proteins 
prepare mucin vesicles.  Munc 18 is required for syntaxin binding and Munc 13-4 primes 
vesicles for fusion-competence (Brose, Rosenmund et al. 2000; Martin 2002; Rizo and 
Sudhof 2002; Brose, Betz et al. 2004).     
In addition to secretion from superficial epithelium goblet cells mucus secretion 
occurs from submucosal glands.  Submucosal glands are innervated by parasympathetic, 
sympathetic, and nonadrenergic noncholinergic nervous systems.  These glands also 
respond to acetylcholine through muscarinic receptors.  However, goblet cells are 
regulated by autocrine/paracrine signaling rather than by nervous control.  Apical P2Y 
purinoreceptors allow goblet cells to respond to ATP and UTP (Davis and Lazarowski 
2008).  It has been shown in airway goblet cell models that P2Y-R activation increases 
the release of mucins as well as more nucleotides (Kreda, Okada et al. 2007).  These 
nucleotides as well as inflammatory stimuli converge onto PLC-mediated pathways 
involving DAG, IP3, and Ca2+ signaling.  Coordination of mucin exocytosis and 
synthesis is observed with mucin hypersecretion.  During inflammatory responses, for 
instance, neutrophiles become activated.  Once activated, they release TNF−α and 
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reactive oxygen species (ROS).  TNF-α increases EGFR expression in airway epithelium, 
which can be triggered by ROS.  In addition, neutrophil elastase can also activate EGFR, 
both of which lead to significant goblet cell degranulation.  This is accompanied by 
further chemokine secretions, which perpetuate the inflammatory response.  Lipid 
mediators, platelet activating factor (PAF), and arachidonic acid have also been shown to 
stimulate mucin secretions (Davis and Dickey 2008). 
Another critical component that regulates mucus production is mucus cell 
hyperplasia.  This process can occur through cellular differentiation and is triggered by 
challenges presented to the cells.  These signals include inflammatory responses, such as 
IL-1β, that converge onto TNFα pathways (Burgel, Escudier et al. 2000).  Mucus cell 
hyperplasia occurs at the expense of progenitor cells, including serous and Clara cells.  
Progenitors produce anti-inflammation, anti-bacterial molecules, and immunomodulatory 
molecules.  Consequently, hyperplasia leads to a loss of this defense in addition to mucus 
hyperproduction.  Prolonged hypersecretory mucin state or other regulatory imbalance 
posses a threat to proper MCC and leads to pathogenesis. 
  
1.5 Mucus Hydration 
 Mucus hydration is a major factor in establishing the viscosity and subsequent 
transport of mucus.  It is proposed that the mucus layer is separated from the underlying 
PCL layer by a surfactant or slip layer (Rubinstein, unpublished data), (Zhang, Craster et 
al. 2003).  Having a lower viscosity than the layers it separates, the slip layer would 
reduce frictional forces as the mucus moves along the PCL surface.  Hydration of this 
layer would alter its volume or height, thus altering mucus transport.  For instance, 
 8 
decreased hydration increases mucus concentration, decreases the slip layer height, and 
slows mucus transport.  As hydration is dependent on ion transport, it becomes clear how 
the interaction of MCC components is required for maintaining homeostasis.  Likewise, 
the velocity of the mucus layer is contingent on the efficiency of cilia beating.   
 In addition to defining osmotic pressures between ASL components, mucins may 
provide a source of lubrication due to their polyanionic charges.  Raviv et al. have 
demonstrated that hydrated ions can act as effective lubricants between sliding charged 
substances (Raviv, Giasson et al. 2003).  An application of this system is likely found in 
the airway.  Charged mucins tethered to the cell surface may repel the charges exerted by 
those found in the mucus layer.  As the charged polymers attached to rubbing surfaces 
demonstrated superior lubrication, the mucin distribution may provide the ASL with a 
means of efficient movement that facilitates clearance.  Such lubrication would also 
increase the productivity of cough clearance (Basser, McMahon et al. 1989).  
 Mucus production and the resulting percent solids of the ASL determine fluid 
movement.  A percent solid of 6% defines a threshold where the osmotic pressure 
between the PCL and mucus layer are equal.  Once this threshold is exceeded in the PCL, 
water travels from the PCL into the mucus layer.  Cilia beating will be inhibited and 
velocity of mucus slowed.  Mucus percent solids may then serve as a predictor of the 
ability to clear mucus.   
 
2.  Ion Transport  
ASL volume requires coordinated water and ion transport regulation and 
ultimately airway surface hydration.  Thus, on the airway surface, epithelial cells must 
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correctly regulate NaCl and water movement in order to maintain the correct environment 
for MCC.  The volume hypothesis predicts active ion transport to maintain an isotonic 
ASL at a volume that facilitates MCC as a means of defense (Matsui, Grubb et al. 1998; 
Boucher 1999; Matsui, Davis et al. 2000).  Recent studies have found evidence for the 
ASL volume hypothesis (Tarran, Grubb et al. 2001).  Furthermore, these studies 
illustrated a feedback mechanism between the ASL and airway epithelia that regulate ion 
transport and volume absorption.  The visionary Kilburn hypothesis explained the upward 
movement of mucus through a stark airway gradient of larger to smaller surface area 
(Kilburn 1968).  Maintenance of a consistent ASL volume along the airway would 
require fluid absorption, which is possible though regulated ion transport. 
Within the airway, water transport is passive while ion transport is active.  The 
epithelial sodium channel (ENaC) allows Na+ to enter the cell from the ASL while the 
cystic fibrosis transmembrane conductance regulator (CFTR) allows Cl- to exit the cell 
into the ASL.  The balance of this ion exchange establishes an ASL volume that allows 
cilia beating and eventually mucus clearance.  As ASL height is altered, Na+ absorption 
and Cl- secretion responds appropriately, in normal epithelia, to readjust the ASL to a 
height approximately equal to the outstretched cilia (Matsui, Grubb et al. 1998; Tarran, 
Button et al. 2005).  The role of ion transport in maintaining ASL height and MCC is 
further elucidated when such pathways are disrupted.  Excised trachea treated with anion 
and liquid secretion inhibitors show significantly reduced mucociliary transport (Ballard, 
Trout et al. 2002).   As CFTR mediates such pathways, it largely contributes to the MCC 
defense in normal airways.   
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Regulation of ion transport includes autocrine and paracrine signaling, mechanical 
stimulation, and proteases (Vallet, Chraibi et al. 1997; Chraibi, Vallet et al. 1998; Rossier 
2004; Tarran 2004; Tarran, Button et al. 2005).  One molecule that regulates ASL height 
indirectly is HCO3-, which is secreted into the ASL at low concentrations (<10mM) 
(Coakley, Grubb et al. 2003).  ASL may be altered by HCO3- levels as it affects the local 
pH and therefore ion channel or ecto-enzyme function.   Among the most potent ASL 
regulators are nucleotides and nucleosides.  ATP is capable of triggering apical P2Y2 
receptors (Mason, Paradiso et al. 1991).  This stimulation inhibits PKC-mediated ENaC 
Na+ absorption while increasing Cl- secretion through Ca2+ mediated, calcium-activated 
chloride channels (CaCC) (Mason, Paradiso et al. 1991).   Autocrine/paracrine regulation 
of CFTR may also occur as ATP and its metabolites are processed by ecto-nucleotidases 
and apyrases.  For instance, adenosine has been shown to regulate ASL height through 
stimulation of CFTR via the adenosine receptor subtype, A2b (Hentchel-Franks, Lozano 
et al. 2004; Huang, Gilmore et al. 2004; Chambers, Constable et al. 2006; Rollins, Burn 
et al. 2008).  The role of soluble mediators, such as adenosine, is speculated as a major 
means of regulating ASL volume (Tarran, Trout et al. 2006). 
 One source of nucleotides is a mechanical stress-dependent release (Burnstock 
2002; Guyot and Hanrahan 2002).  Air movement across the epithelial cells is 
experienced as shear stress (Basser, McMahon et al. 1989).  Although the mechanism is 
unknown this force triggers ATP release into the ASL.  Likewise, cyclic compressive 
stress—another model of tidal breathing—has been shown to release ATP into the ASL.  
Accordingly, nucleotide availability and the resulting regulation of ASL will also be 
dependent on the activity of nucleotidases.   
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 Intracellular signaling is also an important source of ion transport regulation 
(Rossier 2004).  The second messenger cAMP has been shown to inhibit ENaC and 
activate CFTR.  This coordination facilitates Cl- transport as ENaC inhibition 
hyperpolarizes the membrane, which then allows Cl- exit against an unfavorable 
concentration gradient into the ASL.  However, in CF cAMP has been shown to activate 
ENaC.  It would seem that CFTR thus negatively regulates ENaC but through a yet 
defined pathway.  Such interactions may be direct or indirect.  Intracellular domain 
interactions between the two channels have been identified (Kunzelmann, Kiser et al. 
1997).  It is also possible that alterations in intracellular ion concentration and 
cytoskeleton arrangement alter ENaC and CFTR interaction (Ismailov, Berdiev et al. 
1997; Berdiev, Latorre et al. 2001; Okiyoneda and Lukacs 2007).   
Another important means of regulating ion transport is by directly altering ion 
channel function.  As an example, serine proteases such as trypsin and channel activating 
protease, CAP1, have been shown to activate ENaC (Vallet, Chraibi et al. 1997; Chraibi, 
Vallet et al. 1998).  Accordingly, serine proteases such as aprotinin are capable of 
blocking such stimulation (Vuagniaux, Vallet et al. 2000).  Recent evidence suggests that 
CAPs are tethered to the membrane, proximal to ENaC whereas CAP inhibitors are 
soluble within the ASL (Tarran, Trout et al. 2006).  SPLUNC1 was identified as an 
endogenously secreted protein in the airways, which inhibits CAP activated ENaC 
activity (Garcia-Caballero, Rasmussen et al. 2009; Rollins, Garcia-Caballero et al. 2010).  
The balance of CAP and CAP inhibitor availability is likely to be an important means of 
ASL height regulation.  The availability of nucleotides and CAPs are likely molecules 
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that act as ASL sensors.  Such molecules may be responsible for the feedback of ASL 
volume to ion transport regulation. 
 
3.  Cilia 
The efficiency of ciliary beating is dependent on the two MCC components 
previously discussed.  The PCL volume must be maintained at a height sufficient for cilia 
beating, which has been approximated as 7µm (Tarran, Grubb et al. 2001).  The mucus 
load itself is capable of affecting the ciliary beating frequencies (CBF) (Sleigh 1983; 
Sanderson and Dirksen 1989).   Ciliary beating is also influenced by surrounding cilia, 
and in this sense demonstrate self-regulation (Sanderson and Sleigh 1981; Sleigh 1983).  
The mechanism is not yet understood, although beating occurs in a metachronal wave 
with particular coordination with cilia on the same cell (Salathe 2007).  Another source of 
regulation is mechanical deformation of the cell surface, which has also been shown to 
increase CBF (Sanderson and Dirksen 1989).  Such an increase may be due to release of 
nucleotides.  For instance, extracellular ATP may trigger purinergic receptors that—via 
PLC pathways—alter calcium levels and eventually ciliary beating (Braiman and Priel 
2008).  ATP may also signal through a specific, and yet defined, purinergic receptor that 
more directly regulates ciliary beating (Korngreen, Ma et al. 1998; Ma, Korngreen et al. 
2006).  Increases in intracellular calcium levels following purinergic signaling, however, 
is one known mediator in regulating CBF (Braiman and Priel 2008).  In line with this 
purinergic signaling hypothesis, P2Y2-receptor deficient mice show reduced CBF.  
However exogenous addition of ATP and adenosine addition could not recapitulate the 
CBF stimulation resulting from shear stress.  Thus alluding to the involvement of a more 
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complex signaling system (Nakahari 2007).  This signaling molecule also influence ion 
transport that influence the environment into which the cilia extend (Mason, Paradiso et 
al. 1991).  Furthermore, the effectiveness of cilia beating is also dependent on mucus 
composition.  Increased viscosity has been shown to disrupt CBF as well as coordinated 
beating (Gheber, Korngreen et al. 1998).  Regulated MCC component coordination is 
essential for proper cilia beating and is required for homeostasis. 
 
II.  Disease State Mucociliary Clearance 
 Disrupted regulation and coordination of mucociliary components lead to 
impaired mucus clearance and increased susceptibility to infection.  Malfunctioning 
MCC components are observed in diseases such as Cystic Fibrosis, Chronic Obstructive 
Pulmonary Disorder (COPD), and Primary Dyskinesis (PCD) (Imbrie 1981; Quinton 
1983; Mullen, Wright et al. 1985; Saetta, Turato et al. 1997).  Each disorder may arise 
from abnormalities primarily affecting one MCC component but due to the regulatory 
interaction of each component results in impairing the entire MCC system. 
 
Chronic Obstructive Pulmonary Disorder (COPD) 
 COPD is characterized by reduced airflow into and out of the lungs (Hogg, Chu et 
al. 2004).  Exposure to inhaled particulates such as allergens or cigarette smoke initially 
triggers an inflammatory response.  The reduction in airflow is not completely reversible 
and likely due to chronically abnormal inflammatory responses, although the 
pathogenesis is still unclear (Hogg, Chu et al. 2004).  Due to the detection of auto-
antibodies COPD is proposed to be linked to autoimmune disorders (Feghali-Bostwick, 
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Gadgil et al. 2008).   Furthermore, such a disorder may have genetic predispositions as a 
higher percent of smokers who are related develop COPD than those who are unrelated 
(Silverman, Chapman et al. 1998).  Following increased inflammatory responses, heavy 
mucus secretion occurs.  The mucus layer consists of higher percent solids relative to 
healthy individuals yet lower than those of CF patients.   
 Inflammatory pathways trigger increased mucus production and eventually cause 
mucus plugging.  Mucus cell hyperplasia and metaplasia have been observed in COPD. 
(Bergeron and Boulet 2006)  The abnormal regulation of mucus production and section 
represents an MCC response initially elicited to combat the inhaled challenges but once 
misregulated results in harm to the host.  Infiltration of macrophage and neutrophils, for 
instance, follows mucus build up and releases harmful inflammatory contents into the 
airway, as they cannot be properly cleared (Worlitzsch, Tarran et al. 2002; Chmiel and 
Davis 2003; Gibson, Burns et al. 2003). 
 
Cystic Fibrosis 
 Cystic Fibrosis is the most common genetic COPD and illustrates the 
complication arising from abnormal ion transport.  This genetic disease results in a 
mutated chloride channel known as the Cystic Fibrosis Transmembrane Regulator 
(CFTR) (Kerem, Rommens et al. 1989).  The most common mutation is a deleted 
phenylalanine residue at position 508 of the CFTR protein (Kerem, Rommens et al. 1989; 
1990).  Normal expression of CFTR on epithelial cells facilitates chloride efflux and 
subsequent hydration of the ASL (Sheppard and Welsh 1999).  In addition to this source 
of inadequate dehydration, CFTR inhibition of the epithelial sodium channel (ENaC) is 
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lost in CF (Mall, Bleich et al. 1998; Knowles and Boucher 2002; Chmiel and Davis 
2003).  The still elusive molecular mechanism of hyperactive ENaC in CF depends on 
cAMP activation while the second messenger serves to inhibit ENaC in normal cells 
(Knowles, Gatzy et al. 1983; Knowles, Stutts et al. 1983; Boucher, Stutts et al. 1986).  
The combination of both ion transport abnormalities exaggerates the ASL depletion, 
which results in collapsed cilia and a mucus layer of high percent solids(Matsui, Grubb et 
al. 1998).  Mucus stasis ensues and provides opportunities for infection.   
 Chloride transport still occurs in CF epithelial cells through a secondary channel, 
calcium activated chloride channel (CaCC) (Mason, Paradiso et al. 1991).  ATP is a 
known activator of this channel, via a P2Y2 receptor dependent pathway, and becomes 
important for ASL regulation in CF airways (Mason, Paradiso et al. 1991).  Alteration in 
ATPase activity has a large impact in CF airways, which are heavily dependent on this 
secondary chloride channel.  Viral infections have been shown to increase ATPase 
activity and further dehydrate the diseased airway (Tarran, Button et al. 2005). 
 Another consequence of altered CFTR activity is an abnormal pH of the ASL.  In 
addition to chloride conductance, CFTR can conduct bicarbonate and therefore affects the 
pH of the ASL.  The activity of enzymes in the ASL that effect channel activity is 
undoubtedly affected by alterations in the pH of their working environment.  Of 
particular interest channel activating proteins (CAPS) have been shown to regulate 
ENaC.  Understanding the interaction of CAPS and their inhibitors in various pH 
conditions will shed light on other areas of interest for ion transport regulation.   
 Animal models have been generated to aid CF studies.  Mice deficient in CFTR 
failed to show reduced mucous clearance rates (Grubb, Jones et al. 2004).  Furthermore, 
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inflammation and infection were not observed.  This may be explained as chloride 
secretion in lower airways was compensated by CaCC (Mall 2008).  A mouse model that 
demonstrates ASL dehydration is the beta-ENaC overexpressing mouse (Mall, Grubb et 
al. 2004).  Studies with these mice have recently found airway surface dehydration leads 
to airway inflammation.  Neutrophilic inflammation was observed with chronic airway 
mucus obstruction in addition to the emphysema and transient eosinophilic inflammation 
observed.  This model will be useful for studies of airway dehydration and its 
contribution to COPD (Mall, Harkema et al. 2008). 
In contradiction to the hydration defects of CF, type I pseudohypoaldosteronism 
(PHA) is a disorder with excess fluid in the airway.  Here, Na+ absorption through ENaC 
is impaired and, consequently, fluid is not absorbed from the ASL.  Interestingly, in the 
face of this impaired ion transport the mucus layer is able to regulate the excess fluid.  
This low percent solid mucus remains in contact with the underlying cilia.  The abnormal 
ion transport in PHA leads to an increased mucous transport rate when compared to 
normal (Kerem, Bistritzer et al. 1999; Tarran 2004).  
 
Primary Ciliary Dyskinesia (PCD) 
 
 PCD is a genetic disease in which ciliary structure and function develop 
abnormally.  As a result, mucus clearance is impaired and susceptibility to infection 
arises.  In comparison to CF, however, PCD patients have fewer infections and better 
lung function (Kollberg, Mossberg et al. 1978).  Cough clearance may facilitate mucus 
clearance more effectively in PCD patients relative to CF patients, as ASL volume and 
mucus percent solids are not directly impaired.   
 
 17 
 
 
 
 
 
 
4.  Summary 
 
Regulation of mucus production, ion transport, and cilia beating as well as their concerted 
regulation is critical for maintaining lung homeostasis.   Further understandings of the 
mechanisms for these MCC components have prepared the way for novel therapeutic 
targets for diseases with impaired clearance.  Rather than targeting secondary results of 
these diseases such as bacterial infection or viscous mucous, these therapies directly 
target ion transport defects.  These include restoring CFTR function, stimulating 
alternative Cl- channels, and inhibiting Na+ absorption.  Restoring airway surface 
hydration is now possible through inhaled hypertonic saline, which temporarily brings 
water to the airway surface from the osmotic gradient imposed (Donaldson, Bennett et al. 
2006).  Correcting such aberrations will lead to a more properly regulated ASL, restoring 
hydration and ciliary movement, and eventually mucus clearance. 
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CHAPTER 1 FIGURES 
 
 
 
Figure 1.  Model of Airway Ion Transport.  Appropriate hydration of the airway 
surface liquid (ASL) is achieved, as a balance between Cl- efflux and Na+ influx is struck 
at the apical surface of airway epithelial cells.  In addition to Cl- secretion, CFTR is 
coupled to HCO3- secretion.  Together with SLC26, these channels largely influence the 
pH of the ASL.  Once ENaC is cleaved by proteases, the opened channel allows 
absorption of Na+ from the apical surface.  Proper regulation of these ion channels allows 
for an ASL height sufficient for cilia extension and beating.  The overlaying mucus layer 
can then be cleared to remove inhaled pathogens. 
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Figure 2.  Model for the inhibition of channel activating proteases (CAPs).  As 
proteolytic cleavage of ENaC by CAPs enables the channel to conduct Na+ into the cell, 
inhibition of this cleavage reduces ENaC current.  Protease inhibitors such as aprotinin, 
directly inhibit protease function.  Alternatively, inhibitors of ENaC cleavage could bind 
directly to ENaC and block the access of proteases.  SPLUNC1 is an endogenously 
secreted protein in the airways, and has been identified as an inhibitor of ENaC cleavage.  
  
 
 
 
Chapter 2 
SPLUNC1 EXPRESSION REDUCES SURFACE LEVELS OF THE EPITHELIAL 
SODIUM CHANNEL (ENAC) IN XENOPUS LAEVIS OOCYTES 
 
 
Abstract 
 
 Throughout the body, the epithelial Na+ channel (ENaC) plays a critical role in 
salt and liquid homeostasis.  In cystic fibrosis airways, for instance, improper regulation 
of ENaC results in hyperabsorption of sodium that causes dehydration of airway surface 
liquid. This dysregulation then contributes to mucus stasis and chronic lung infections.  
ENaC is known to undergo proteolytic cleavage, which is required for its ability to 
conduct Na+ ions.  We have previously shown that the short, palate lung and nasal 
epithelial clone (SPLUNC1) binds to and inhibits ENaC in both airway epithelia and in 
Xenopus laevis oocytes.  In this study, we found that SPLUNC1 was more potent at 
inhibiting ENaC than either SPLUNC2 or long PLUNC1 (LPLUNC1), two other PLUNC 
family proteins that are also expressed in airway epithelia.  Furthermore, we were able to 
shed light on the potential mechanism of SPLUNC1’s inhibition of ENaC.  While 
SPLUNC1 did not inhibit proteolytic activity of trypsin, it significantly reduced ENaC 
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currents by reducing the number of ENaCs in the plasma membrane. A better 
understanding of ENaC’s regulation by endogenous inhibitors may aid in the 
development of novel therapies designed to inhibit hyperactive ENaC in cystic fibrosis 
epithelia. 
 
Introduction 
 ENaC is the rate-limiting step for Na+ absorption in the airways (Gaillard, Kota et 
al. ; Kunzelmann and Mall 2002; Rossier and Stutts 2008).  The importance of 
appropriately regulated ion transport is illustrated by the pathogenesis that results when 
this channel fails to function correctly.  For example, hyperabsorption of Na+ through 
ENaC has been proposed as an initiating event in cystic fibrosis (CF) lung disease 
(Knowles and Boucher 2002; Chmiel and Davis 2003).  This likely occurs because Na+ 
hyperabsorption contributes to mucus dehydration and mucus stasis, which prevents 
clearance of inhaled pathogens (Knowles and Boucher 2002), (Chmiel and Davis 2003), 
(Matsui, Grubb et al. 1998). Furthermore, Na+ hyperabsorption, volume depletion, and 
inflammation have recently been demonstrated in transgenic mice overexpressing ENaC, 
thus directly linking ENaC and the initiation of chronic lung disease (Mall, Grubb et al. 
2004).  In contrast, as ENaC is down regulated in the monogenic disorder, 
pseudohypoaldosteronism, it leads to an abundance of airway surface liquid and mucus 
transport rates that are significantly increased above normal levels (Kerem, Bistritzer et 
al. 1999).   
 ENaC is regulated by intracellular second messengers including cAMP and PIP2 
(Ma, Chou et al. 2007; Pochynyuk, Bugaj et al. 2008).  However, extracellular serine 
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proteases also regulate ENaC (Hughey, Carattino et al. 2007; Rossier and Stutts 2008).  
Rossier and colleagues initially identified a membrane-bound serine protease that acts as 
a channel activating protease (CAP) which they termed CAP1 (Vallet, Chraibi et al. 
1997).  The activation of ENaC by CAP1 can be mimicked by external addition of trypsin 
and the effects are not additive, indicating that CAP1 and trypsin act via the same 
pathway.  Additional CAPs, termed CAP2 (TMPRSS4) and CAP3 (matriptase) have also 
been identified as being able to activate ENaC by increasing its open probability (Po), 
without any significant change in channel density or conductance (Vuagniaux, Vallet et 
al. 2000; Rossier 2004).  The effect of these CAPs can be blocked by the Kuitz-type 
serine protease inhibitor aprotinin (Vallet, Chraibi et al. 1997; Vuagniaux, Vallet et al. 
2000) which prevents the cleavage of ENaC and the subsequent conduction of Na+ in 
both primary human bronchial epithelial cultures (HBECs) and Xenopus oocytes 
(Bridges, Newton et al. 2001) (Donaldson, Hirsh et al. 2002; Myerburg, Butterworth et al. 
2006).    
 The Palate Lung and Nasal epithelial Clone (PLUNC) family can be subdivided 
into short (SPLUNC) and long (LPLUNC) proteins which contain either one or two 
subdomains, respectively (Bingle and Craven 2002). In this classification, the original 
protein called PLUNC is now SPLUNC1 (Bingle and Gorr 2004).  SPLUNC1 is 
expressed in submucosal glands of normal individuals (Bingle, Cross et al. 2005), and 
expression is increased in cystic fibrosis (CF) lungs, especially in the surface epithelia of 
the conducting airways (Bingle, Barnes et al. 2007).  SPLUNC1 is an abundant protein 
secreted into the ASL of HBECs (Campos, Abreu et al. 2004). Early characterization of 
SPLUNC1’s sequence identity uncovered some structural homology with anti-microbial 
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proteins and incited theories that SPLUNC1 would similarly function in a direct innate 
host defense capacity (Bingle, LeClair et al. 2004).  To date, however, this theory 
remains uncertain.  Investigators have reported minimal anti-microbial function of 
SPLUNC1 (Bartlett, Hicks et al. 2008) and no binding to lipopolysaccaride, as might be 
expected from its strong homology to lipopolysaccaride binding proteins (Campos, Abreu 
et al. 2004).  In contrast to its putative anti-microbial actions, we identified SPLUNC1 as 
a potent inhibitor of ENaC in both Xenopus oocytes and in human airway epithelia 
(Garcia-Caballero, Rasmussen et al. 2009).  We also found that SPLUNC1 binds to 
ENaC and prevents its proteolytic cleavage by serine proteases including trypsin, CAP1 
and CAP2 (Garcia-Caballero, Rasmussen et al. 2009).  Since little is known about the 
SPLUNC1-ENaC interaction, we further explored this relationship and here we report 
that among the other PLUNC family members expressed in HBECs, SPLUNC1 alone 
significantly inhibits ENaC.  We also demonstrate that SPLUNC1 exerts its effects on 
ENaC by lowering the number of ENaCs available for cleavage at the plasma membrane.  
 
Results 
 We have previously demonstrated that SPLUNC1 is secreted into the media of 
SPLUNC1-injected oocytes where it binds to the extracellular loops of the α, β, γ ENaC 
subunits, resulting in ENaC inhibition (Garcia-Caballero, Rasmussen et al. 2009).  Data-
mining of existing gene array data revealed that other PLUNC family members are 
expressed in our HBEC system, suggesting that other PLUNCs may be secreted into the 
airway surface liquid and could also regulate ENaC (Ribeiro, Hurd et al. 2009).  
Specifically, LPLUNC1 was endogenously expressed in HBECs and SPLUNC2 was not 
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expressed under basal conditions. After exposing HBECs to supernatant of mucopurulent 
material (SMM), which is derived from CF airway secretions and acts as a powerful pro-
inflammatory agent (Ribeiro, Paradiso et al. 2005), LPLUNC1 and SPLUNC1 expression 
were not altered.   However, SPLUNC2 expression increased by 2.4 and 1.5 fold at 6 and 
24 h post-SMM addition, respectively (Ribeiro, Hurd et al. 2009).  To test whether these 
other PLUNC family members could also affect ENaC activity, we expressed 
α,β,γ ENaC in Xenopus oocytes and measured their subsequent amiloride-sensitive 
current under control conditions and following co-injection with either SPLUNC1, 
SPLUNC2, or LPLUNC1.  ENaC currents were reduced by ~70% when SPLUNC1 was 
co-injected into the oocytes (Figure 1).  In contrast, co-injection of SPLUNC2, which has 
24% amino acid homology to SPLUNC1, or LPLUNC1, which has 2 domains rather than 
the single domain of the SPLUNC subgroup, and has 30% amino acid homology to 
SPLUNC1, had no significant effect on ENaC activity (Figure 1).  
 To understand how SPLUNC1 regulated ENaC, we examined whether SPLUNC1 
could alter the proteolytic activity of trypsin.  We have previously observed significant 
inhibition of ENaC by SPLUNC1 at 50 ng/ml, which is equivalent to 1.79 nM.  At this 
same concentration, SPLUNC1 did not alter the ability of trypsin to cleave a serine 
protease-specific fluorogenic substrate, while the trypsin-specific inhibitor aprotinin, also 
administered at 1.79 nM, abolished proteolytic cleavage (Figure 2).  Thus, we conclude 
that the regulation of ENaC by SPLUNC1 does not result from direct protease inhibition.    
 We have previously shown that SPLUNC1 can inhibit both basal and trypsin-
stimulated ENaC currents (Garcia-Caballero, Rasmussen et al. 2009).  The most 
straightforward explanation for this phenomenon is that that the number of ENaCs in the 
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plasma membrane had been reduced by SPLUNC1. To test this hypothesis directly, we 
surface biotinylated oocytes and then probed for αENaC surface expression levels in the 
presence and absence of SPLUNC1.  SPLUNC1 indeed decreased the total amount of 
αENaC in the plasma membrane, as compared to controls that did not express SPLUNC1 
(Figure 3A).  In contrast SPLUNC1 did not affect whole-cell ENaC protein levels (Figure 
3B).  
In order to confirm SPLUNC1’s ability to reduce ENaC levels in the plasma membrane, 
we used the sulfhydryl-reactive reagent [2-(trimethylammonium)ethyl 
methanethiosulfonate, bromide] (MTSET), which locks ENaC containing a S518C 
mutation in the β subunit (βS518C) into the fully open position and thus yields an electrical 
approximation of the number of active channels in the plasma membrane (Anantharam, 
Tian et al. 2006).  With this system, a reduction in α, βS518C, γ-ENaC current in the 
presence of MTSET would indicate fewer ENaCs in the plasma membrane, which we 
observed in oocytes coinjected with SPLUNC1 (Figure 3C). Moreover, the fold-
stimulation of α, βS518C, γ-ENaC currents by MTSET was 5.32 ± 0.45 while groups co-
expressing SPLUNC1 had an 8.05 ± 0.48 fold increase.  This indicates that ENaC 
resident on the cell surface in SPLUNC1 expressing oocytes reside in a low open 
probability state. Together with the enhanced fold-stimulation by trypsin (Garcia-
Caballero, Rasmussen et al. 2009), these results indicate that SPLUNC1 limits proteolysis 
of ENaC by reducing ENaC surface density (Figure 3C). 
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Discussion 
 We have previously reported that SPLUNC1 inhibits ENaC, likely via direct, 
extracellular binding to all three ENaC subunits (Garcia-Caballero, Rasmussen et al. 
2009).  Following on from these findings, we were curious to know whether the other 
PLUNC family members that are expressed in our HBEC system would produce similar 
inhibitory effects.  While SPLUNC1 inhibits ENaC by ~70%, SPLUNC2 and LPLUNC1 
do not significantly inhibit ENaC (Figure 1).  These data are in keeping with our previous 
observations that the knockdown of SPLUNC1 to greater than 90% by shRNA 
upregulated ENaC activity in HBECs and led to ASL volume hyperabsorption, despite 
expression of other PLUNC family members in these epithelia(Garcia-Caballero, 
Rasmussen et al. 2009).  Interestingly, SPLUNC1 is able to reduce ENaC currents by 
70% when applied at 50 ng/ml (1.79 nM) either in the Xenopus oocytes or in HBECs 
lacking endogenous SPLUNC1(Garcia-Caballero, Rasmussen et al. 2009), while this 
concentration of SPLUNC1 produces negligible direct effects on the proteolytic activity 
of trypsin, suggesting that SPLUNC1 does not act as a protease inhibitor (Figure 2).  
Thus, based on this and our previous data (Garcia-Caballero, Rasmussen et al. 2009), we 
conclude that SPLUNC1 acts by directly interacting with ENaC and not by direct 
inhibition of extracellular proteases.   
 The mechanism of SPLUNC1’s interaction with ENaC is currently unknown.  
However, SPLUNC1 inhibits both basal and trypsin-activated ENaC currents (Garcia-
Caballero, Rasmussen et al. 2009), which may provide additional insight into its 
mechanism of action.  The macroscopic ENaC current (I) is a product of the single 
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channel conductance (g) multiplied by both the open probability (Po) and the number of 
channels in the plasma membrane (N).  Proteolytically-induced changes in I have been 
mainly attributed to altered Po and can be rapidly reversed by trypsin exposure (Vallet, 
Chraibi et al. 1997).  In contrast, we found that acute trypsin exposure failed to fully 
reverse the effects of SPLUNC1 (Garcia-Caballero, Rasmussen et al. 2009), suggesting 
that the effects of SPLUNC1 are not exclusively limited to changes in Po.  Our present 
data indicate that SPLUNC1 reduces the number of ENaCs subunits at the plasma 
membrane, without affecting overall cellular ENaC levels (Figure 3A, B).  These data are 
consistent with the effects of SPLUNC1 on ENaC currents (Figure 3C). For example, 
such a reduction in N would serve to lower basal ENaC currents in addition to preventing 
MTSET from further activating ENaC.  While we have demonstrated this mechanism 
exclusively in oocytes (Figure 3), we have previously shown that SPLUNC1 decreases 
the ENaC/trypsin-sensitive potential difference in HBECs, suggesting that SPLUNC1 
inhibits ENaC in a similar mechanism in airway epithelia (Garcia-Caballero, Rasmussen 
et al. 2009).   
 ENaC is trafficked to and from the plasma membrane in a highly regulated 
fashion (Rotin, Kanelis et al. 2001; Gormley, Dong et al. 2003; Butterworth, Edinger et 
al. 2009) and we speculate that SPLUNC1’s binding to ENaC may directly induce a 
conformational change in ENaC that triggers its internalization. Alternatively, SPLUNC1 
has several putative adaptor protein 2 (AP2) binding domains and adaptor proteins have 
been identified as components in the ENaC internalization pathway (Shimkets, Lifton et 
al. 1997; Wiemuth, Ke et al. 2007).  Thus, a complex containing SPLUNC1, ENaC and 
AP2 may facilitate ENaC’s internalization. Finally, SPLUNC1 may also act as a pore 
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blocker, in a fashion analogous to amiloride, though with less reversible binding (Schild, 
Schneeberger et al. 1997).  Such behavior could lead to a reduction in both basal and 
protease-activated ENaC currents and cannot be formerly excluded although this mode of 
inhibition alone is inconsistent with the observed decrease in N (Figure 3).  
 In summary, we have shown that SPLUNC1, but not other PLUNC family 
members, induces a potent inhibition of macroscopic ENaC current.  While the 
mechanism of SPLUNC1’s inhibition of ENaC is not fully understood, we have found 
that SPLUNC1 is capable of reducing the number of ENaC multimers at the plasma 
membrane.  This is the first report of an endogenously secreted protein that can facilitate 
removal of ENaC from the plasma membrane. 
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Methods 
SPLUNC1 protein purification. V5/6His-tagged SPLUNC1 was stably expressed in 
HEK293 cells and purified from their media as previously described using ethanol and 
acetone precipitation21. Media collected from HEK293 cells not expressing SPLUNC1 
was purified using the same ethanol/acetone precipitation method and was used as a 
control.  
 
Oocyte studies.  Xenopus laevis oocytes were harvested and injected as described(Garcia-
Caballero, Rasmussen et al. 2009). In brief, defolliculated healthy stage V–VI oocytes 
were injected with 0.3 ng of cRNA of each ENaC subunit. Injected oocytes were kept in 
modified Barth’s saline (in mM: 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.3 Ca(NO3)2, 0.41 
CaCl2, 0.82 MgSO4, and 15 HEPES, adjusted to pH 7.35 with Tris). Oocytes were 
studied 24 h after injection using the two-electrode voltage clamp technique as previously 
described(Donaldson, Hirsh et al. 2002; Garcia-Caballero, Rasmussen et al. 2009). 
Oocytes were clamped at a holding potential of −60 mV. The change in amiloride-
sensitive whole cell current as an indicator of ENaC activity was determined by 
subtracting the corresponding current value measured in the presence of 10 µM amiloride 
from that measured before the application of amiloride. For each group, whole cell 
currents were presented as relative currents to control oocytes injected with ENaC and 
water.  Thus, these control groups are assigned a relative current of 1, as units reported 
are nA/nA. 
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Western Blotting.  Protein was harvested from Xenopus oocytes, resolved using SDS-
PAGE and transferred to PVDF. The membrane was then probed using a anti-αENaC or 
anti-V5 monoclonal antibodies (Invitrogen)) as previously described (Garcia-Caballero, 
Rasmussen et al. 2009).   
 
Surface labeling.  Xenopus oocytes were injected with V5-CT(C-terminus)-tagged 
α, untagged−β,γ rat ENaC subunits (0.3 ng each) ± V5/6His-tagged SPLUNC1 (1 ng).  
After 24 h, eggs (70 per experimental condition) were pre-chilled on ice for 30 minutes 
and labeled with 0.7 mg/ml sulfo-NHS-biotin in MBS-Ca++ (mM), 85 NaCl, 1 KCl, 2.4 
NaHCO3, 0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3), 16.3 hepes titrated to pH 8.0 with 
NaOH, while tumbling gently for 20 min at 4°C.  Oocytes were washed twice with 
chilled MBS-Ca++ buffer and incubated in MBS-Ca++ buffer with 100 mM glycine for 10 
min at 4°C to quench free biotin.  Eggs were washed again three times with chilled MBS-
Ca2+ buffer.   Proteins were extracted as previously described(Garcia-Caballero, 
Rasmussen et al. 2009).  Total inputs were taken from whole cell samples representing 
4% of total protein.  Solubilized proteins were incubated with 100 µl of neutravidin beads 
(Pierce) overnight while tumbling at 4°C.  Samples were washed twice with (mM) 500 
NaCl 50 Tris pH 7.5 buffer and once with 150 NaCl 50 Tris pH 7.5 buffer.  Laemmli 
buffer was added and samples were loaded on a 15% gradient Tris-glycine gel after 
incubation for 10 minutes at 96°C.  Samples were transferred to PDVF membranes and 
western blot analysis was performed using anti-V5 (Invitrogen) and anti-actin (Chemicon 
International) monoclonal antibodies. 
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Trypsin MCA Assay. The trypsin fluorogenic substrate assay was performed using 96 
well black plates (Corning Costar). Boc-Gln-Ala-Arg-MCA (100 µM; Peptides 
International) was added to each well in 100 µl Ringer total volume. Aprotinin (Sigma-
Aldrich) or SPLUNC1 as appropriate were then combined with the substrate, and trypsin 
(Sigma-Aldrich) was then added at 1 U/ml to initiate the reaction.   Boc-Gln-Ala-Arg-
MCA was excited at 380 ± 5 nm and emission was collected at timed intervals at 460 ± 
15 nm using a Tecan Infinite multi-plate reader.   
 
Statistical analyses:  All data are presented as the mean ± SE for n experiments. Each 
oocyte study was repeated on three separate occasions. Differences between means were 
tested for statistical significance using paired or unpaired t tests or their non-parametric 
equivalent as appropriate to the experiment. Differences between groups were judged 
using ANOVA.  From such comparisons, differences yielding P ≤ 0.05 were judged to be 
significant. 
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CHAPTER 2 FIGURES 
 
 
 
 
 
 
 
Figure 1. The effect of PLUNC family members on ENaC activity.   Current is 
displayed relative to amiloride-sensitive current from α,β,γ ENaC-expressing oocytes 
(ctrl, white bar; n=18).  Oocytes co-expressing SPLUNC1 showed a ~70% reduction in 
ENaC current (p <0.0001; n=22).  However, those co-expressing SPLUNC2 (n=22) or 
oocytes co-expressing LPLUNC1 had no significant ENaC current reduction (n=17). * 
denotes p<0.05 different to control oocytes expressing α,β,γ ENaC.   
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Figure 2. SPLUNC1 is not a protease inhibitor. The trypsin-specific fluorogenic 
trypsin substrate Boc-Gln-Ala-Arg-MCA, emits fluorescence upon cleavage.  Trypsin (1 
U/ml, ■); trypsin and aprotinin (1.79 nM, ●); trypsin and SPLUNC1 (1.79 nM, ▲) .  
Boc-Gln-Ala-Arg-MCA alone (o). All n=4.  
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Figure 3. SPLUNC1 decreases the number of αENaC subunits in the plasma 
membrane. A, Surface biotinylation of αENaC shows that plasma membrane ENaC is 
decreased following coexpression with SPLUNC1 in Xenopus oocytes. Samples were 
analyzed by Western blot using a anti-V5 (for V5/6His-tagged SPLUNC1 and for V5-
CT-tagged αENaC) monoclonal antibody Lane 1, control; 2, αβγENaC, 3, αβγENaC & 
SPLUNC1. Total lysate per lane was equivalent to 3-4 oocytes and was run on a 10% 
Gel. B, Whole cell western blot of oocytes probing for αENaC (top), SPLUNC1 and 
actin (bottom) shows that total ENaC levels are not decreased by SPLUNC1.   Total 
lysate per lane was equivalent to 3-4 oocytes and was run on a 12% Gel.  C, Addition of 
MTSET to ENaC containing the βS518C mutant increases ENaC Po to 1.0 when 
coexpressed in oocytes yet the overall current is still reduced by SPLUNC1 expression.  
Open bars, control. Closed bars, MTSET addition, n = 6 for each group.  * denotes 
p<0.05 different to control for MTSET treated groups; † denotes p<0.05 different to 
control for SPLUNC1 coinjected groups.   
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
THE ACTIVE SITE OF SPLUNC1 SHARES 40% HOMOLOGY WITH THE ENAC 
INHIBITORY PEPTIDE 
 
 
Abstract 
 Hyperabsorption of Na+ through the epithelial Na+ channel (ENaC) contributes 
to cystic fibrosis (CF) lung disease and thus emphasizes the need to further understand 
the regulation of this channel.  The short, palate lung and nasal epithelial clone 
(SPLUNC1) is expressed in the submucosal glands and surface epithelia of the 
conducting airways and was recently identified as secreted protein, which negatively 
regulates ENaC.  Since SPLUNC1 is a small, secreted protein (256 amino acids), 
identifying its active site may enable us to design a therapeutic peptide that inhibits 
ENaC.  In this study we examined the ability of SPLUNC1 truncants to inhibit ENaC in 
Xenopus oocytes.  The peptide sequence of functional mutants revealed that residues 22 
to 39 were ~40% homologous to the ENaC inhibitory peptides, α26 and γ43, that are 
released from the extracellular loop of ENaC following proteolytic cleavage.  SPLUNC1 
truncants that contained this region maintained the ability to inhibit ENaC, whereas those 
that lacked this region did not.  We designed a peptide to mimic this 18 amino acid region 
of SPLUNC1 termed, S18, and found that it inhibited ENaC current in Xenopus oocytes.  
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We applied this labeled peptide to primary human bronchial epithelial cultures (HBECs) 
and observed increased the airway surface liquid (ASL) height, as compared to controls.  
Further understanding the regulation of ENaC by this region of SPLUNC1 and the S18 
peptide may provide insight for new therapeutic avenues for CF patients.   
 
Introduction 
As the airways are constantly exposed to inhaled particulates that may be 
infectious or noxious, they rely on efficient mucociliary clearance (MCC) to remove such 
threats.  MCC is dependent on three coordinated components including ion transport, 
mucin secretion, and ciliary beating. Improper regulation of any component disrupts 
MCC, leaving the lung vulnerable to infection. Among these components, ion transport is 
critical for the hydration of the airway surface liquid (ASL) to volumes sufficient for 
ciliary extension and beating.  Hydration also regulates the appropriate percent solids 
within the mucus layer that rests above the ASL, which is critical for efficient mucus 
clearance.   The importance of precise regulation and coordination of these pathways 
becomes evident, as initiating events in chronic airway diseases, such as cystic fibrosis 
(CF), have been traced back to the failure of ion transport.  Specifically ENaC is known 
to be hyperabsorptive in the airway epithelia of CF patients and contributes to dehydrated 
ASL, collapsed cilia, and high percent solid mucus.  Collectively, as the MCC defense 
mechanism fails under these misregulated circumstances, CF patients are unable to clear 
inhaled pathogens and face life-threatening infections.   
Reducing hyperactive ENaC within the lungs of CF patients holds important 
therapeutic potential and requires a clearer understanding of ENaC regulation.   
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Currently, secondary messenger signals such as cAMP and PIP2 are known to regulate 
the function of ENaC (Rossier 2004).  More recently, ENaC is known to be cleaved and 
activated by extracellular serine proteases, which are termed channel-activating proteases 
(CAPs) (Vallet, Chraibi et al. 1997).  In CF, protease levels are also known to be 
upregulated, leading to increased ENaC activity.  Inhibition of these CAPs results in 
decreased ENaC conductance and increased MCC.   Accordingly, further elucidation of 
ENaC regulation by protease cleavage is required so that novel therapies can be targeted 
to inhibit cleavage and activation of hyperactive ENaC. 
Previous studies have identified several membrane bound CAPs and have 
indicated that CAP inhibitors are soluble (Garcia-Caballero, Rasmussen et al. 2009).  
Among these potential soluble inhibitors SPLUNC1 was identified, which proved to be a 
potent inhibitor of ENaC and thus a candidate volume-sensing molecule (Garcia-
Caballero, Rasmussen et al. 2009).   As SPLUNC1 is a small protein (256 peptides) that 
is secreted into the ASL (Campos, Abreu et al. 2004), identifying its active site may 
provide insight for development of a yet smaller peptide inhibitor of hyperactive ENaC.  
In hopes of developing a therapeutic peptide for CF patients, we examined the ability of 
full-length and truncated SPLUNC1 to inhibit ENaC current.  In this study we analyzed 
the peptide sequence of functional SPLUNC1 truncants to those of inhibitory peptides 
that originate from the cleavage of the extracellular loops of α and γ ENaC (Carattino, 
Sheng et al. 2006; Carattino, Hughey et al. 2008).  These peptides are referred to as α26 
and γ43, which indicate the subunit of ENaC from which they are derived and the number 
of amino acids of which they are composed.  Interestingly, the peptide sequence spanning 
from residues 22 to 39 of SPLUNC1 bear a striking resemblance to these inhibitory 
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peptides.  The homology between these 18 amino acids of SPLUNC1 and α26 is 40% 
while the homology to γ43 is 35%.  Cumulatively, this region of SPLUNC1 shares 78% 
homology with both α26 and γ43.  We hypothesized that this region of SPLUNC1 may 
be responsible for the inhibition of ENaC current.  Further, four proline residues in this 
18 amino acid region of SPLUNC1 are homologous to proline residue that were 
necessary for the function of the ENaC inhibitory peptides.  We speculate that these 
prolines (P25, 27, 33, and 38) may be necessary for ENaC inhibitions by SPLUNC1.  We 
observed a reduction in ENaC inhibition in SPLUNC1 truncants containing proline point 
mutations.  Finally, we designed a mimetic peptide to the proposed active site of 
SPLUNC1 termed, S18.  We found this peptide to be functional, as it decreased ENaC 
activity in Xenopus laevis oocytes and increased HBEC ASL height following S18 
administration.   
 
 
Results 
 It was recently show that peptide fragments released from the extracellular 
domains of ENaC following proteolytic cleavage, termed α26 and γ43, have inhibitory 
effects on ENaC (Carattino, Sheng et al. 2006; Carattino, Hughey et al. 2008). As 
SPLUNC1 is a small, secreted protein that also inhibits ENaC, we searched for any 
sequence similarities between SPLUNC1 and these peptides.  Amino acid sequence 
alignment revealed a striking similarity.  From residues 22 to 39, SPLUNC1 shares 40% 
homology with α26 and 35% homology with γ43 (Figure 1).  Additionally, within this 
homology region of SPLUNC1 we found four proline residues, which were necessary for 
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function of the ENaC inhibitory peptide fragments (Carattino, Sheng et al. 2006; 
Carattino, Hughey et al. 2008). We proposed that this high homology region of 
SPLUNC1’s sequence might be the active site for its inhibition of ENaC. 
 To test this hypothesis, we designed several SPLUNC1 truncants (Figure 2).  
Deletions up to 85% of full length SPLUNC1 from the C-terminal retained the putative 
active site while deletions of 88.75% bisected this site and 92.5% removed the site.  
These SPLUNC1 truncants were then co-injected with α, β, γ-ENaC subunits into 
Xenopus oocytes and current was recorded by voltage clamp technique.  Currents from 
control oocytes injected with α, β, γ-ENaC and water were set to 1 nA/nA and compared 
to those co-expressing SPLUNC1 truncants.  As seen in Figures 3 and 4, significant 
ENaC inhibition was observed for SPLUNC1 deletions up to 85%, which retained the 
putative active site, but this inhibition was lost for deletions that disrupted the site 
(control 1 ± 0.04, SPLUNC1 0.52 ± 0.03, SPLUNC1del30% 0.389± 0.09, SPLUNC1 del60% 
0.45 ± 0.06, SPLUNC1del85% 0.49 ± 0.06, SPLUNC1del88.75% 1.01 ± 0.13, 
SPLUNC1del92.5% 1.03 ± 0.06; n=12-18 per group, p<0.05).  Interestingly, point mutations 
of proline residues P25, 27A and P33, 38A within the putative active site of the 
SPLUNC1del85% truncant reduced the efficiency of ENaC inhibition (Figure 5).  This 
suggests that these proline residues are important for SPLUNC1’s function and that point 
mutations of all residues, P25, 27, 33, 38A may abolish its ENaC inhibitory effects.   
 Understanding that this high homology region of SPLUNC1 is important for 
inhibition of ENaC, we designed a peptide that mimics residues 22 to 39 of SPLUNC1.  
We first tested the effectiveness of this 18 amino acid SPLUNC1 peptide, S18, by 
measuring amiloride-sensitive current in oocytes expressing α, β, γ-ENaC subunits by 
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voltage clamp technique.  Incubation for 90 minutes of 10µM S18 significantly reduced 
baseline current by 51% and trypsin-activated current by 52% (Figure 6).  Of note, acute 
addition at the same concentration rendered no effect on ENaC current (Figure 7). 
 We then questioned if the S18 peptide could effect ASL height regulation in 
normal primary human bronchial epithelial cultures (HBECs).  During preliminary work, 
S18 was applied at 100µM at the start of a 24-hour time course and ASL height was 
measured by confocal microscopy.   As compared to cultures treated with vehicle alone, 
HBECs exposed to S18 exhibited a higher ASL height over time (Appendix, Figure 1).  
These pilot studies suggest that the S18 peptide could increase ASL height by inhibiting 
Na+ absorption through ENaC and strongly encourage further investigations with S18. 
 
Discussion 
 As SPLUNC1 is an endogenously secreted protein in the airways, which has 
known ENaC inhibitory properties (Garcia-Caballero, Rasmussen et al. 2009; Rollins, 
Garcia-Caballero et al. 2010), characterizing the region of this protein with strong 
homology to the ENaC inhibitory peptides, α26 and γ43 is an important step for 
identifying the active site.  We engineered SPLUNC1 truncants in hopes of isolating the 
region of the protein that was responsible for ENaC inhibition.  We considered residues 
22 to 39 of SPLUNC1 to be the putative active site, as it held strong homology to the 
ENaC inhibitory peptide fragments.  Voltage clamp current recordings of oocytes co-
injected with α, β, γ-ENaC and these truncants revealed significant ENaC inhibition by 
truncants including the putative active site, as compared to control oocytes co-injected 
with α, β, γ-ENaC and water alone. Although SPLUNC1 function was observed in 
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truncates deleting as much as 85% of the full-length protein from the C-terminus, 
deletions of 88.75 and 92.5% bisected and omitted the putative active site, respectively, 
and had no inhibitory effect on ENaC current.  From these findings we concluded that 
this region of SPLUNC1 was necessary for its inhibition of ENaC. 
 A span of 8 residues from positions 211 to 218 of the α26 ENaC inhibitory 
peptide was identified as the key inhibitory region (Carattino, Passero et al. 2008).  
Residues L1, P2, H3, P4, and L8 were specifically required for inhibitory activity.  
Interestingly, from residues 24 to 32 of the proposed active site of SPLUNC1 a 75% 
homology can be found with the 8 residue key inhibitory domain of α26.  Further, critical 
residues L1, P2, P4, and L8 of α26 are conserved in the putative active site of SPLUNC1.  
We point mutated resides P25 and P27 of SPLUNC1, which correspond to P2 and P4 of 
the key inhibitory region of α26.  We also point mutated the remaining prolines of the 
SPLUNC1 active site P33, 38 to alanines.  Setting the normalized ENaC current for α, β 
,γ-ENaC expressing control oocytes to 1 nA/nA, we compared the current of oocytes co-
expressing SPLUNC1del85%, P25, 27A SPLUNC1del85%, and P33, 38A SPLUNC1del85% to 
controls.   Co-expression of SPLUNC1del85% reduced ENaC current by 76%, while co-
expression of P25, 27A SPLUNC1del85% reduced ENaC current by only 32%.  Co-
expression with P33, 38A SPLUNC1del85% still reduced current by 59%.   This suggests 
that P25 and P27 of SPLUNC1, which correlate to P2 and P4 of the 8-residue key 
inhibitory domain of α26 are important for efficient ENaC inhibition.   
 Based on our findings that the 18 amino acids spanning residues 22 to 39 of 
SPLUNC1 play an important role in the protein’s ability to inhibit ENaC, we designed a 
peptide corresponding to this region of SPLUNC1.  This peptide was termed S18 and had 
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the sequence, GGLPVPLDQTLPLNVNPA.  Oocytes expressing α, β, γ-ENaC that were 
incubated for 90 minutes with 10µM S18 peptide exhibited a significant, 51% reduction 
in current, as compared to these oocytes in the presence of vehicle alone (Figure 6).  
Acute addition of 10µM S18 peptide, however, did not reduce ENaC current (Figure 7).  
These data may provide clues into the mechanism of action of S18.  As we previously 
demonstrated that SPLUNC1 reduces the number of ENaCs in the membrane as a means 
of reducing macroscopic current (Rollins, Garcia-Caballero et al. 2010), the required 
incubation time for S18 to function may indicate a similar means of ENaC inhibition.  
Further, the 52% reduction in trypsin-activated ENaC current by S18 suggests that the 
number of membrane localized channels available for cleavage-dependant activation is 
reduced.  Characterizing how SPLUNC1 and the S18 peptide inhibits ENaC remain 
important areas of research.  It may be found that full-length SPLUNC1 and the S18 
peptide have different mechanisms for inhibiting ENaC.  Perhaps through the proposed 
active site, SPLUNC1 and the S18 peptide can affect conformational changes in ENaC, 
which stimulates internalization.  Specifically, the ENaC inhibitory peptides have been 
proposed to prevent conformational changes that facilitate Na+ conductance and 
SPLUNC1’s active site could functions similarly (Kleyman, Carattino et al. 2009).  It has 
also been proposed that longer membrane retention times facilitate ENaC internalization, 
which could help explain the change in N by SPLUNC1 or S18 (Butterworth, Edinger et 
al. 2009).  The reduction in N of ENaC by SPLUNC1 is not observed with the ENaC 
inhibitory peptides and suggests that SPLUNC1 may have a different or perhaps an 
additional mechanism of action.  Lost binding domains for other proteins or steric 
differences, however, may make the S18 peptide less effective than SPLUNC1 for 
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blocking CAP access to ENaC (Garcia-Caballero, Rasmussen et al. 2009).  Analysis of 
ENaC cleavage assays in the presence of the S18 peptide will be useful tools for 
addressing this important question. 
 Our pilot studies with S18 effects on ASL height regulation in HBECs also 
encourage further investigations with this peptide.  We found that normal HBECs treated 
with 100µM S18 maintained a higher ASL height over a 24-hour time course, as 
compared to untreated cultures (Appendix, Figure 1).  We speculate that S18 inhibits 
ENaC in HBECs, as in our studies using injected oocytes.  Reducing Na+ conductance 
through ENaC would slow HBEC’s ability to absorb excess ASL over time, as we 
observed.  This insight of S18’s function in HBECs raises further questions, though.  
Within the complex environment of the HBEC system, it will be important to know if 
S18’s effect on ASL height regulation is ENaC-specific.   Understanding S18’s ability to 
affect the Po and N of ENaCs within HBECs should also be addressed.  In addition to 
these investigations, testing for the ability of S18 to work in CF airways will provide 
important insight for a potentially novel therapeutic tool.   
 
 
Methods 
Sequence Analysis:  Homologous sequences between SPLUNC1 and peptides, α26 and 
γ43, were identified using protein BLAST searches.   
 
Molecular Engineering of Constructs:  Cloning primers were engineered to incorporate 
the N-terminal, signal peptide containing region of SPLUNC1 and to truncate the C-
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terminus at various lengths.  Resulting constructs included, bisected, or removed the 
region homologous to the ENaC inhibitory peptide.  Additionally, four prolines were 
mutated to alanines within this region of homology to α26 and γ43.  This point mutations 
were engineered within the SPLUNC1del85% truncant and termed SPLUNC1del85% 
P25,27A and SPLUNC1del85% P33, and 38A. 
 
Oocyte studies.  Xenopus laevis oocytes were harvested and injected as described 
(Garcia-Caballero, Rasmussen et al. 2009). In brief, defolliculated healthy stage V–VI 
oocytes were injected with 0.3 ng of cRNA of each ENaC subunit. Injected oocytes were 
kept in modified Barth’s saline (in mM: 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.3 Ca(NO3)2, 
0.41 CaCl2, 0.82 MgSO4, and 15 HEPES, adjusted to pH 7.35 with Tris). Oocytes were 
studied 24 hours after injection using the two-electrode voltage clamp technique as 
previously described (Donaldson, Hirsh et al. 2002; Garcia-Caballero, Rasmussen et al. 
2009). Oocytes were clamped at a holding potential of -60 mV. The change in amiloride-
sensitive whole cell current indicated of ENaC activity and was determined by 
subtracting the corresponding current value measured in the presence of 10 µM amiloride 
from that measured before the application of amiloride. For each group, whole cell 
currents were presented as relative currents to control oocytes injected with ENaC and 
water.  Thus, these control groups are assigned a relative current of 1, as units reported 
are nA/nA. 
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Peptide Design:  The S18 peptide was synthesized and purified by the UNC Peptide 
Synthesis Facility with sequence, GGLPVPLDQTLPLNVNPA.  The peptide was amino-
terminal acetylated and caroboxy-terminal amidated 
 
ASL Height Measurement.  20 µl PBS containing 2 mg/ml Texas red–dextran (10 kD) 
was added to the mucosal surface of the bronchial cultures. For all studies, 100 µl PFC 
was added mucosally to prevent evaporation of the ASL. Cultures were then be placed in 
a chamber that has a serosal reservoir containing 80 µl of modified TES-buffered Ringer 
solution and placed on the stage of an inverted confocal microscope(Tarran, Grubb et al. 
2001). To measure the average height of the ASL, five predetermined points on the 
culture (one central, four circumferential) were XZ scanned.  Images were analyzed using 
ImageJ (NIH freeware) software by placing several regions of interest around the ASL 
that were then averaged for each image and the mean height calibrated based on a 5122 
pixel image corresponding to 125 µm2. 
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Chapter 3 Figures 
 
 
 
Figure 1:  Alignment of SPLUNC1 to inhibitory peptides, α26 and γ43, cleaved 
from ENaC’s extracellular loops.  Alignment to α26 residues are shown in red and 
those to γ43 are shown in blue while alignments to both are shown in purple.   
 
α26            4   GALPHPL-QRLRTPPPP ---  NPA   2  homology with SPLUNC1, 40%  
                        G  LP   PL  Q  L           P       NPA 
SPLUNC1 22  GGLPVPLDQTL   ----   PLNVNPA  39 homology with peptides, 78% 
                           G P               +          PL   V 
γ43            11     GTPPRFLNLI   -----   PLLV          24 homology with SPLUNC1, 35% 
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Figure 2:  SPLUNC1 and SPLUNC1 mutants examined for ability to inhibit ENaC.  
N-terminal signal peptide sequence (amino acids 1-19)  is indicated in red.  The putative 
active site (amino acids 22-39) is illustrated in green with proline shown as purple bars or 
red bars once mutated to alanine. 
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Figure 3:  Comparison of ENaC inhibition by full-length and truncated SPLUNC1 
at pH 7.4.  Significant inhibition  (n-13, p<0.0001) of ENaC is observed with full-length, 
60%, 30%, and 15%.  All truncates include the putative active site of SPLUNC1. 
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Figure 4:  SPLUNC1 truncates lacking the active site fail to inhibit ENaC.  While the 
SPLUNC1del85% contains the active site and inhibits ENaC, the SPLUNC1del88.75% and 
SPLUNC1del92.5% truncants, which bisect or omit the active site of SPLUNC1, 
respectively, lack inhibitory function (n=12). 
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Figure 5:  Proline point mutations within SPLUNC1’s Active Site reduce its 
inhibitory effects.  Point mutation P25, 27A or P33, 38A within the active site reduced 
the effectiveness of SPLUNC1del85% to inhibit ENaC in co-expressing oocytes, as 
compared to ENaC expressing oocytes alone (Ctrl), (n=6). 
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Figure 6:  Inhibition of ENaC current by addition of S18 peptide.  Significant ENaC 
inhibition ( n=6, p<0.0001) is seen following 90 minute incubation with 10µM of the S18 
peptide (Black Bars) reduces baseline and trypsin-activated ENaC current in Xenopus 
Oocytes expressing α, β, γ-ENaC subunits., as compared to ENaC-expressing oocytes in 
vehicle alone (White Bars).   
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Figure 7:  No inhibition of ENaC Current by acute addition of S18 peptide.  Acute 
addition of S18 peptide had no effect on ENaC inhibition (Black Bars), as compared to 
ENaC-expressing oocytes in vehicle alone (White Bars), (n=10).   
 
 
  
 
 
 
Chapter 4 
ACIDIC ENVIRONEMNTS, LIKE THOSE IN CYSTIC FIBROSIS AIRWAYS, 
PREVENT SPLUNC1’S INHIBITION OF ENAC 
 
Abstract 
  
 
 Ion transport is a key component of mucociliary clearance (MCC), which the 
airways rely upon for successful removal of inhaled pathogens.  Abnormal ion transport 
occurs in Cystic Fibrosis, as CFTR fails to secrete Cl- and as ENaC’s absorption of Na+ is 
hyperactive.  This results in dehydrated airway surface liquid (ASL) that leads to higher 
percent solid mucus and collapsed cilia.  Under these conditions, MCC fails and CF 
patients face life-threatening infections.  Recent investigations have uncovered that 
impaired bicarbonate secretion due to the loss of functional CFTR affects the pH of CF 
ASL.  As CFTR contributes to NaHCO3 secretions, its absence in CF leads to an acidic 
environment.  In this report, we show that the endogenously secreted inhibitor of ENaC, 
SPLUNC1, fails to impede Na+ absorption in acidic environments.  We propose that this 
pH-dependency could explain the loss of SPLUNC1 function in CF, despite its 
abundance on the protein level within the ASL.  Further, we demonstrate that buffer 
correction of the acidic conditions in CF primary bronchial epithelial cultures (HBECs) 
recovers ENaC’s responsiveness to inhibitors and increases the ASL height.  We also 
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present a novel approach to thin-film pH measurements, as a powerful tool for 
investigating pH effects on airway cultures.  Together, this work describes important 
consequences of misregulated pH in CF airways and highlights the need for further 
investigations to develop corrective therapies for CF patients.   
 
Introduction 
 
 As a genetic disorder, CF is characterized by a dysfunctional CFTR anion channel 
(Welsh and Smith 1993).  One of the initiating events in the disease, however, has been 
linked to the hyperabsorption of sodium through ENaC, as this channel is misregulated in 
the absence of CFTR (Knowles and Boucher 2002).  This imbalance of ion transport 
contributes to a dehydrated airway surface liquid (ASL) to levels insufficient for cilia 
extension.  Once collapsed, ciliary beating is inhibited and inhaled pathogens cannot be 
cleared.  Furthermore, the loss of functional CFTR adversely alters the pH of the ASL, as 
CFTR is capable of conducting HCO3- and affects Cl- coupled NaHCO3 transport 
(Poulsen, Fischer et al. 1994; Choi, Lee et al. 2001).  As a consequence CF airways 
become more acidic than normal airways (Wine 2006). 
 While dehydrated ASL and increased percent solids of mucus are well 
characterized consequences of abnormal ion transport in CF airways, the abnormal pH 
resulting from misregulated ion transport may further disrupt airway physiology.  
Hyperactivity of ENaC in CF has been attributed to lost negative regulation by CFTR, 
but the acidic environment has also been proposed to be a contributing factor (Collier and 
Snyder 2009). Accordingly, understanding how endogenous inhibitors of ENaC behave 
in the acidic environment of CF airways will be important for development of novel 
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therapies.  SPLUNC1, for instance, has recently been identified as an endogenously 
secreted inhibitor of ENaC in the normal airways (Garcia-Caballero, Rasmussen et al. 
2009; Rollins, Garcia-Caballero et al. 2010).  Despite the abundance of SPLUNC1 
protein in the ASL of CF HBECS ENaC remains hyperactive.  As exogenous protease 
inhibitors such as aprotinin can still inhibit ENaC in CF airways, we propose that 
SPLUNC1’s action may be defective, rather than ENaC’s.  To test this hypothesis, we 
examined the ability of SPLUNC1 to inhibit ENaC over a range of pH’s.  Here, we report 
maximal inhibition of ENaC by SPLUNC1 in physiological pH ranges and a loss of 
inhibition in acidic environments.  In Chapter 3, we demonstrated ENaC inhibition by 
SPLUNC1 truncants that contain the putative active site between residues 22 to 39.  For 
this study, we examined their effects in the acidic conditions of CF ASL.  Like full-length 
SPLUNC1, these truncants lose their ability to inhibit ENaC in acidic conditions.  These 
findings of pH dependency provide a possible explanation for the loss of SPLUNC1 
function in CF airways, despite its abundance at the protein level.  
 As pH affects this important component of airway physiology, we then questioned 
if reducing the acidic environment of CF HBECs could restore more normal ASL volume 
regulation.    Towards these efforts, we selected biological buffers with alkaline pH 
buffering ranges for administration to CF HBECs.  Indeed, CF HBECs treated with 
buffer solutions maintained a higher ASL, as compared to untreated CF HBECs.  
Additionally, CF HBECs with reduced acidity demonstrated spontaneous ENaC 
inhibition over time, as is seen in normal HBECs.  We attribute this inhibition of ENaC 
over time to the accumulation of soluble inhibitors, such as SPLUNC1.  As such, these 
results suggest that pH-dependent SPLUNC1 activity occurs in HBECs. 
 56 
 While pH measurements of lavaged ASL from normal and CF HBECs reveal an 
acidic environment in CF cultures (Coakley, Grubb et al. 2003), we aimed to take thin-
film pH measurements from these cultures.  This approach would provide a more 
accurate understanding of the pH in native conditions and during treatment with alkaline 
buffers.  This work establishes a novel approach for thin-film pH measurements over a 
broad pH range by combining two pH-sensitive fluorophores.   Using this technique, we 
drew a correlation to the increase in ASL height to the reduced acidity of CF HBEC ASL. 
 
 
Results 
 
 Previous studies have reported an abnormal acidic environment in CF airways 
(Coakley, Grubb et al. 2003).  As exogenous inhibitors, such as aprotinin, can still inhibit 
ENaC in CF HBECs we speculated that endogenous ENaC inhibitors are malfunctioning 
in the acidic enviorment.  As an endogenous regulator of ENaC, SPLUNC1 activity was 
examined under various pH conditions.  Xenopus oocytes were co0injected with α, β, γ-
ENaC and SPLUNC1 or H2O, as a control, and incubated in a range of buffered 
solutions.  We found a pH-dependent inhibition of ENaC (Figure 1).  Maximal ENaC 
inhibition by SPLUNC1 occurred in physiological pH conditions mimicking those of 
normal HBECs, but was lost in the acidic environment like those found in CF HBECs.  
We also tested for any pH-dependent activity of SPLUNC1 mutants that are deleted from 
the C-terminus, but include the previously identified active site of SPLUNC1. Consistent 
with the behavior of full-length SPLUNC1, these truncants SPLUNC1del30%, SPLUNC1 
del60%, and SPLUNC1del85% maintain the ability to inhibit ENaC at pH 7.4 but were 
ineffective at pH 6.0 (Figure 2). 
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 Having identified a potential explanation for the loss of ENaC inhibition in the 
acidic environment of CF airways, we attempted to correct the abnormal pH in CF 
HBECs by buffer administration.  Biological buffers were selected with alkaline 
buffering ranges in hopes of reducing the acidity of CF HBECs (Table 1).  Proposing that 
larger molecules would be retained longer in the ASL to sustain their buffering capacity, 
we also considered the molecular weight of each buffer.  Basically buffered solutions 
were apically administered to CF HBECs in efforts to reduce ASL acidity and to 
potentially improve the ability of CF cultures to regulate ASL height under these altered 
conditions.  As an indicator of ion transport function in these cultures, ASL height was 
measured by confocal microscopy over the time course of buffer administration.  We 
found that biological buffers POPSO, AMPSO, and CAPSO initially set to pH 8.5 were 
effective in preventing hypersaborption.  Compared to control cultures in pH 7.4 PBS, 
treated CF HBECs maintained a higher ASL of the 24-hour time course (Figure 3).   
 To address how this buffer treatment affected ENaC activity we measured the 
thin-film potential difference (PD) of CF HBECs.  PD measurements on normal cultures 
reveal that ENaC activity can be inhibited spontaneously, as endogenous inhibitors 
accumulate over time (Garcia-Caballero, Rasmussen et al. 2009).  Here, we show that 
this spontaneous inhibition over time does not occur in untreated CF cultures, but is 
recovered in CF HBECs treated with a solution buffered to pH 8.2 (Figure 4).  
Additionally, the spontaneous ENaC inhibition in normal HBECs can be reversed by the 
application of exogenous trypsin, which cleaves and activates ENaC (Garcia-Caballero, 
Rasmussen et al. 2009).  This activation does not occur in CF HBECs, as these ENaCs 
 58 
appear to be maximally active.  Treatment with the basically buffered solution, however, 
reestablished ENaC activation by the exogenous trypsin administration (Figure 4).   
 In order to more accurately describe the pH environment in CF cultures in native 
conditions and during buffer treatment, we attempted to take thin-film pH measurements 
on these cultures.  This was accomplished by combining two pH-sensitive fluorophores, 
SNARF-1 and FITC (Figure 5), and by recording the appropriate excitation and emission 
wavelength ratios of these dyes while on the HBECs.  Over a 24-hour time course, the pH 
was calculated from these measurements (Figure 6).   We found a correlation between 
decreased ASL acidity and ASL height.    The buffer with the largest molecular weight, 
POPSO, also sustained buffering effects and ASL height increases for longer periods of 
time.  Additionally, we noticed that the thin-film pH measurement in CF HBECs at the 0 
hour time point was already more acidic than the initial pH 8.5 solution.  To address this 
discrepancy, we asked if pH measurements from a lavage of the buffer solution would 
reveal its acidification.  Surprisingly, however, there was no change in pH between pre- 
and post-application of the buffer solution (Figure 7).  This suggested, perhaps, that fixed 
components on the HBECs surface were contributing to the acidic environment.  One 
possible source of fixed charges is the collection of mucins, which are tethered to airway 
epithelia (Raynal, Hardingham et al. 2003).   
 
 
Discussion 
 
 As compared to normal airways, the environment experienced by SPLUNC1 once 
it is secreted into CF ASL differs in several important regards to that of normal epithelia 
and such environmental influences may, in fact, dictate the effectiveness whereby 
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SPLUNC1 inhibits ENaC current.  Specifically, the ASL where SPLUNC1 attempts to 
bind and inhibit ENaC is subject to abnormal bicarbonate transport in CF airways and 
becomes more acidic than normal airways (Coakley, Grubb et al. 2003).  Our data 
suggest that the acidic ASL of CF airways prevent the proper inhibition of ENaC by 
SPLUNC1.   
 Our voltage clamp data studies showed that SPLUNC1 inhibits ENaC in normal 
physiological pH conditions, but fails to do so in acidic environments, which mimic those 
of CF airways (Figure 1).  The abnormal pH environment could alter the confirmation of 
SPLUNC1 to prevent its binding to ENaC.   As we found SPLUNC1 truncants to be 
functional in normal pH conditions with as much as 85% of the protein deleted from the 
C-terminus, there are few possibilities for pH-sensitive SPLUNC1 conformational 
changes.   Additionally, the functional 18 amino acid SPLUNC1 peptide, S18, has only 
one charged residue, D29.   The extracellular loops of ENaC, though, are also exposed to 
the acidic environment and may have pH-induced conformational changes that prevent 
SPLUNC1 binding.  Within the α-ENaC subunit, three histidine residues (H283, 326, and 
327), for instance, are subject to protonation in acidic conditions, which could perhaps 
mediate SPLUNC1 interactions.  Utilizing point mutants at specific pH sensitive residues 
within SPLUNC1 and ENaC to record current in various pH conditions may shed light on 
the binding site of these proteins.   
 Recent work explained that resetting the osmotic forces in CF airways by 
hypertonic saline could restore mucociliary clearance, and we wondered if resetting pH 
could be similarly effective (Donaldson, Bennett et al. 2006).  In efforts to reduce CF 
ASL acidity, we applied biological buffers with alkaline pH-buffering ranges, which 
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included POPSO, CAPSO, and AMPSO.  Initially set to a pH of 8.5, these buffers 
increased the ASL height of CF HBECs over a 24-hour time course, as compared to 
cultures treated with PBS buffered to pH 7.4 (Figure 4).  While ASL height regulation is 
highly complex, this finding is encouraging for a new approach in restoring mucociliary 
clearance for CF patients. Identifying how these regulatory components are affected by 
buffer treatment will be key studies for this goal.  Here, we demonstrated that recovered 
responsiveness of ENaC to endogenous inhibitors during buffer treatment (Figure 4).  
This is likely a critical component of this recovered homeostasis, as ASL height also 
increased during buffer treatment (Figure 3).  Thin-film measurements show that freshly 
washed normal HBECs have high ENaC activity, which can be spontaneously inactivated 
over time as endogenous inhibitors, such as SPLUNC1, accumulate (Garcia-Caballero, 
Rasmussen et al. 2009).  These measurements in CF HBECs reveal that the accumulation 
of inhibitors fails to reduce ENaC activity in the natively acidic environments (Figure 4).  
CF HBECs treated with HEPES buffered solution to pH 8.2, however, regained 
responsiveness to inhibitors over time.  Additionally, ENaC activity was maximal in CF 
cultures, as exogenous trypsin administration could not increase thin-film PD 
measurements.  Trypsin-activated current was also recovered in buffer-treated cultures 
(Figure 4).  Though further investigations are required to describe buffer effects on ion 
secretion, for instance, this work demonstrates that sodium hyperabsorption through 
ENaC my be halted in less acidic conditions.  
 Using our novel approach for thin-film pH measurements, we recorded the pH of 
buffered CF HBECs over the same time course.  Administration of buffer increased the 
pH of CF HBECs to levels approaching normal conditions.  Interestingly, the buffer with 
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the largest molecular weight, POPSO, established a larger ASL height increase and 
sustained its buffering effects for longer.  Potentially, buffers with larger molecular could 
be retained longer in the ASL, as absorption through the monolayer is impeded based on 
size exclusion.   
 This work describes important effects of pH on components of ASL height 
regulation.  Pursuit of this phenomenon appears to be a fruitful area of research for 
recovering ASL height homeostasis.  Our data suggest that therapies aimed to 
reconstitute normal physiological pH conditions for CF patients could improve MCC.  
Further understanding of pH-induced conformational changes in ENaC or its inhibitors, 
such as SPLUNC1, may allow for the development of compounds that bind and inhibit 
ENaC in these abnormal conditions.  Additionally, as channel activating proteases 
(CAPs) have recently been identified as a major regulatory component of ENaC activity, 
it will also be necessary to characterize the role of acidic pH in these specific interaction.  
Ultimately, work in this field could lead to a new approach for treating impaired MCC in 
CF. 
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Methods 
 
Biological Buffer Treatment:  Buffer solutions set to 290 mOsm were composed of either  
Piperazine-1,4-bis(2-hydroxypropanesulfonic acid) dihydrate (POPSO), 3-
(Cyclohexylamino)-2-hydroxy-1-propanesulfonic acid, CAPSO Free Acid (CAPSO), or 
N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO).  
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20µl of these solutions were added apically to HBECs at the start of the 24-hour time 
course.   
 
Measurement of Transepithelial Voltage (Vt).  A macroelectrode (polyethylene tubing 
with 3 M KCl and 4% agar) was placed in the serosal bath and a 3 M KCl-filled glass 
microelectrode positioned by a micromanipulator into the ASL to stably record Vt. Vts 
were recorded while the cultures were bathed in a low bicarbonate modified Ringer 
solution. PFC was added to the mucosal surface during the period of recording to avoid 
ASL evaporation(Tarran, Grubb et al. 2001) 
 
Thin Film pH Measurements. HBECs were apically loaded with a solution of combined 
pH-sensitive dyes.  50 µl of 20 mg/ml SNARF and FITC were administered to detect the 
pH of cultures in basic and acidic ranges.  Fluorescence was measured at time points 0, 2, 
8, 24, and 48 hours to monitor the resulting pH of the ASL. SNARF was excited at 530 
nm and the emission ratio of 580/640nm was used to detect basic pHs.  Acidic pHs were 
detectable by measuring the FITC excitation ratio of 490/440nm with the emission taken 
at 520nm.  These measurements were compared to HBECs loaded with dye in PBS and to 
a range of pH standards recorded at the same settings.  These pH measurements were 
recorded in a plate reader with three separate HBEC donor codes.   
 
ASL Height Measurement.  20 µl PBS containing 2 mg/ml Texas red–dextran (10 kD) 
were added to the mucosal surface of the bronchial cultures. For all studies, 100 µl PFC 
was added mucosally to prevent evaporation of the ASL. Cultures were then be placed in 
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a chamber that has a serosal reservoir containing 80 µl of modified TES-buffered Ringer 
solution and placed on the stage of an inverted confocal microscope (Tarran, Grubb et al. 
2001). To measure the average height of the ASL, five predetermined points on the 
culture (one central, four circumferential) were XZ scanned.  Images were analyzed using 
ImageJ (NIH freeware) software by placing several regions of interest around the ASL 
that were then averaged for each image and the mean height calibrated based on a 5122 
pixel image corresponding to 125 µm2. 
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Chapter 4 Figures 
 
 
 
Figure 1:  pH-sensitive ENaC inhibition by SPLUNC1.  Relative to ENaC current, 
referenced to 1.0 nA/nA, SPLUNC1 demonstrates a pH-dependent inhibition of ENaC.  
Maximum inhibition is observed in physiological ranges, and lost in acidic conditions, 
which are characteristic of CF ASL pH conditions. 
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Figure 2:  Comparison of ENaC inhibition by full-length and truncated SPLUNC1 
at pH 6.0.  No significant inhibition of ENaC is observed with full-length, 60%, 30%, 
and 15% in acidic conditions.  All truncates include the putative active site of SPLUNC1. 
(n=12) 
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Table 1:  List of basic biological buffers applied to CF ASL. 
Compound: POPSO AMPSO CAPSO HEPES 
MW: 362.42 227.28 237.32 238.3 
pH Buffer 
Range: 7.2–8.5 8.3–9.7 8.9–10.3 6.8–8.2 
Structure 	   	   	   	  
 67 
 
 
 
 
Figure 3:  Correction of acidic ASL pH in CF HBECS increases ASL Height.  CF 
HBECs buffered by solutions of POPSO (diamonds), AMPSO (squares), or CAPSO 
(triangles) set to pH 8.5 show increased ASL height, as compared to cultures exposed to 
PBS set to pH 7.4  (average of 3 CF HBEC codes, n=3 per code). 
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Figure 4:  Basically buffered HBECs exhibit spontaneous ENaC inhibition over 
time.  In contrast to the endogenously acidic ASL conditions of CF HBECs, cultures 
buffered to less acidic ranges mimic NL HBECs, as soluble CAP inhibitors reduce ENaC 
conductance and lower Vt over time. 
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Figure 5.  Combined  solution of pH-sensitive fluorophores, SNARF-1 and FITC 
detects a broad range of pHs.  For a solution composed of SNARF-1 and FITC, A)  the 
440/480 nm excitation ratio of FITC allows for detection of acidic pHs while B) the 
580/460 nm emission ratio of SNARF-1 provides pH measurements in the alkaline 
ranges.   
 
 
A B
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Figure 6:  Reduced acidity of CF HBEC ASL in buffer treated cultures. Thin-film 
pH measurments of CF HBECs ASL reveal that buffer solutions of POPSO (diamonds), 
AMPSO (squares), or CAPSO (triangles) initially set to pH 8.5 reduce the acidity, as 
compared cultures treated with PBS initially set to pH 7.4. (n=3) 
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Figure 7:  Unchanged pH measurments of buffer solution pre- and post-application 
to CF HBECs.  Lavaged ASL of buffer-treated HBECs retain the same pH as the buffer 
solution initially added.  (n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
 
 
 
 As therapies for CF patients have begun to target abnormal ion transport directly, 
we aimed to investigate new avenues for such interventions.  Reducing the 
hyperabsorption of Na+ through ENaC could prevent the dehydration of the ASL and 
improve the mucociliary clearance of inhaled pathogen (Knowles and Boucher 2002).  
Towards this goal, we examined how the endogenously secreted inhibitor of ENaC, 
SPLUNC1, functions in normal cells and why its function is lost in CF. Previously, we 
demonstrated that SPLUNC1 prevents proteolytic cleavage and activation of ENaC 
(Garcia-Caballero, Rasmussen et al. 2009).  Here, we show that SPLUNC1 also functions 
to reduce the number of ENaCs in the membrane (Rollins, Garcia-Caballero et al. 2010).  
Further characterization of the importance of SPLUNC1 in ion transport and ASL height 
homeostasis encouraged our search for the active site of this protein.    We identified a 
region of SPLUNC1 that has 40% homology to the ENaC inhibitory peptide fragment, 
α26.  Using SPLUNC1 truncants, we found that this region was required for ENaC 
inhibition.  Further, we found that an 18 amino acid peptide, S18, which corresponds to 
this region of SPLUNC1 was sufficient to inhibit ENaC. 
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 In addition to considering the activity of SPLUNC1 in healthy airways, we asked 
how the environment of CF airways contributes to the loss of SPLUNC1’s inhibition of 
ENaC.  Specifically, as misregulated NaHCO3 transport occurs in the absence of CFTR, 
we focused on the abnormal acid environment of CF ASL (Poulsen, Fischer et al. 1994; 
Choi, Lee et al. 2001; Coakley, Grubb et al. 2003). We found these pH conditions to 
adversely affect the ability of SPLUNC1 to inhibit ENaC.  We attempted to correct the 
acidic ASL of CF HBECs by the apical application of biological buffers.  Once restored 
to normal physiological pH, CF HBECs recovered the ability to respond to endogenous 
inhibitors and were able to regulate an ASL height sufficient for cilia extension.  To more 
accurately asses changes in pH, we designed a novel approach to measure thin-film pH.  
This technique enabled us to trace the increase in pH of treated cultures and correlate it 
with physiological responses. 
 These studies provided additional questions.  Having identified a functional 
peptide that inhibits ENaC current, we will examine if S18 is effective in the acidic 
environment of CF HBECs.  Our data with SPLUNC1 and SPLUNC1 truncants suggest 
that ENaC conformational changes in an acidic pH may explain the loss of SPLUNC1’s 
binding and inhibition.  Addressing the potential pH dependence of S18 will be 
instructive for research aimed to examine it use as a therapeutic tool for CF. Specific 
studies into the pH-induced conformational changes of ENaC would also be fruitful, as 
this may facilitate the design of compound that could bind and inhibit ENaC in 
environments similar to those of CF airways.  Based on our results, buffer treatment of 
acidic CF ASL in HBECs was effective to restore more normal components of ASL 
height regulation.  As ASL height homeostasis is a complex process, the exhaustive 
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effects of buffer treatments have yet to be described.  Our work, however, both with S18 
peptide and buffer treatments for CF patients could become a new approach for 
improving MCC and encourages further investigation in these areas.
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Appendix 
 
Supporting Preliminary Data 
 
 
 
 
 
Figure 1:  Increased ASL height in normal HBECs treated with S18 peptide.  
HBECs treated with S18 peptide maintain a larger ASL Height over a 24-hour time 
course, as compared to untreated cultures.  (n=4) 
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